Technical Analysis for EXAS - Exact Sciences Corporation

Grade Last Price % Change Price Change
grade C 53.83 -1.12% -0.61
EXAS closed down 1.12 percent on Friday, December 8, 2017, on approximately normal volume. It was able to find support at its 50 day moving average. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
Track This Stock
Watchlist Portfolio
Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Strong Up Up Down
See historical EXAS trend table...

Date Alert Name Type % Chg
Dec 8 50 DMA Support Bullish 0.00%
Dec 8 Lower Bollinger Band Walk Other 0.00%
Dec 8 Wide Bands Range Expansion 0.00%
Dec 8 Oversold Stochastic Weakness 0.00%
Dec 7 50 DMA Support Bullish -1.12%
Dec 7 Lower Bollinger Band Walk Other -1.12%
Dec 7 Wide Bands Range Expansion -1.12%
Dec 7 Lower Bollinger Band Touch Weakness -1.12%
Dec 7 Oversold Stochastic Weakness -1.12%
Dec 6 50 DMA Support Bullish 0.19%

Older signals for EXAS ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio.
Basic chart:

Profile
Exact Sciences Corporation, a molecular diagnostics company, focuses on developing diagnostic screening products for the early detection and prevention of colorectal pre-cancer and cancer. The company develops the Cologuard, a non-invasive stool-based DNA colorectal cancer screening test that is designed to detect pre-cancerous lesions or polyps, and each of the four stages of colorectal cancer. Its Cologuard test includes proprietary and patented methods that isolate and analyze the human DNA that are shed into stool every day from the exfoliation of cells that line the colon; and also protein marker to detect blood in the stool, utilizing an antibody-based fecal immunochemical test. The company's stool-based DNA colorectal cancer screening technology also focuses on the inflammatory bowel disease. It has collaboration, license, and purchase agreement with Genzyme Corporation, as well as with Mayo Clinic for developing tests to detect other gastro-intestinal cancers, primarily esophageal and pancreatic cancer. Exact Sciences Corporation was founded in 1995 and is headquartered in Madison, Wisconsin.
Is EXAS a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 1 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 63.6
52 Week Low 13.05
Average Volume 1,648,100
200-Day Moving Average 38.2547
50-Day Moving Average 53.5021
20-Day Moving Average 57.5873
10-Day Moving Average 56.311
Average True Range 2.2274
ADX 26.14
+DI 18.72
-DI 23.69
Chandelier Exit (Long, 3 ATRs ) 56.9178
Chandelier Exit (Short, 3 ATRs ) 59.2222
Upper Bollinger Band 61.8278
Lower Bollinger Band 53.3468
Percent B (%b) 0.06
BandWidth 14.727205
MACD Line 0.1062
MACD Signal Line 1.0829
MACD Histogram -0.9767
Fundamentals Value
Market Cap 6.41 Billion
Num Shares 119 Million
EPS -1.29
Price-to-Earnings (P/E) Ratio -41.73
Price-to-Sales 34.69
Price-to-Book 10.86
PEG Ratio -1.87
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 56.91
Resistance 3 (R3) 57.13 56.34 56.39
Resistance 2 (R2) 56.34 55.55 56.22 56.22
Resistance 1 (R1) 55.08 55.07 54.69 54.86 56.05
Pivot Point 54.29 54.29 54.09 54.17 54.29
Support 1 (S1) 53.03 53.50 52.64 52.81 51.61
Support 2 (S2) 52.24 53.02 52.12 51.44
Support 3 (S3) 50.98 52.24 51.27
Support 4 (S4) 50.76